IIT RESEARCH INSTITUTE

IIT Research Institute specializes in preclinical research and development across physical, engineering, and life sciences, with deep expertise in toxicology, pharmacology, and drug safety evaluation. The contractor conducts non-GLP and GLP-compliant dose-ranging, maximum-tolerated dose, and safety studies in rodent and canine models, supporting the development of novel small-molecule therapeutics and biologics. Their technical capabilities include in vivo pharmacokinetic and pharmacodynamic analysis, immunologic targeting of solid tumors, infectious disease modeling, and mechanistic evaluation of first-in-class candidates such as CD206 agonists and monoclonal antibody therapies. A key differentiator is their ability to design and execute complex, multi-species toxicology programs that bridge early discovery and IND-enabling studies, with a strong focus on immunotherapies and niche oncology applications. The organization maintains a sustained and primary relationship with the Department of Health and Human Services, delivering critical preclinical support for drug development initiatives across NIH, CDC, and other HHS components. Their work consistently supports HHS priorities in cancer prevention, infectious disease therapeutics, and nicotine reduction technologies, demonstrating a trusted, long-term partnership rooted in scientific rigor and regulatory readiness. IIT Research Institute’s core industry focus lies in NAICS 541715 and 541714, encompassing non-biotech and biotech R&D for pharmaceutical and biomedical applications. They specialize in early-stage drug development pipelines, particularly in immuno-oncology, neuropharmacology, and antimicrobial agents, positioning them as a specialized provider for government-funded translational research programs seeking robust preclinical data packages. As a nonprofit research institute headquartered in Chicago, Illinois, IIT Research Institute operates as an 8H entity with no formal government certifications beyond its structural designation. Their geographic presence is centered in the Midwest, with a national footprint driven by federal contracts. They serve as a mission-aligned R&D partner for public health agencies, emphasizing scientific integrity and regulatory compliance in high-stakes drug development environments.